Anal HPV prevalence exceeds genital detection in female transplant recipients

C Hillen; C Sachs; A Jaeger; K Prieske; A Kaufmann; M Lütgehetmann; B Schmalfeldt; M Sterneck; L Wölber

doi:10.1055/s-0042-1756869

Geburtshilfe und Frauenheilkunde, Inhaltsverzeichnis

Geburtshilfe Frauenheilkd 2022; 82(10): e92-e93
DOI: 10.1055/s-0042-1756869

Abstracts | DGGG

Anal HPV prevalence exceeds genital detection in female transplant recipients

C Hillen

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

,

C Sachs

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

,

A Jaeger

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

,

K Prieske

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

,

A Kaufmann

²Charité – Universitätsmedizin Berlin, Klinik für Gynäkologie, Berlin, Deutschland

,

M Lütgehetmann

³Universitätsklinikum Hamburg-Eppendorf, Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Hamburg, Deutschland

,

B Schmalfeldt

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

,

M Sterneck

⁴Universitätsklinikum Hamburg-Eppendorf, I. Medizinische Klinik und Poliklinik, Fachbereich Lebertransplantation, Hamburg, Deutschland

,

L Wölber

¹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland

› Institutsangaben

Abstract

Volltext

Objective Transplant recipients receiving immunosuppressive therapy have a higher risk of developing anogenital HPV-related (pre)malignancies. We investigated the prevalence of anal and cervical high-risk (hr) HPV infection in female transplant recipients.

Methods Women (n=201) after kidney (n=108) or liver (n=103) transplantation with at least one year after transplantation were HPV tested and genotyped (cobas 6800; Roche diagnostics and Anyplex™ II HPV28; Seegene) at anal and cervical sites on swabs (anal: Bruker eSwab™ system; cervical: Rovers Cervex-Brush). A questionnaire captured sexual behaviour, medical treatment history and demographic data.

Results A cervical hrHPV infection was detected in 32 (15.9%) of the 201 included patients. The most prevalent genotype was HPV16 (31%). No significant difference in HPV prevalence between liver (15.05%) and kidney (17.3%) was found. Increased hrHPV prevalence was not attributable to transplant specific risk factors like type and duration of immunosuppressive therapy. Anal hrHPV showed an overall prevalence of 20.3% (40/197), HPV16 was detected in 17.5% (7/40). The co-prevalence of hrHPV detected in anal and cervical sites was 68.8%. 28/32 patients with cervical hrHPV infection attended clinical follow-up and intraepithelial neoplasia was detected in 3 women (1xCIN2, 1xCIN3, 1x VaIN3). The HPV vaccination rate was 12.4% (25/201) and 68% (17/25) of patients received their vaccination before first sexual intercourse.

Summary Data indicates that cervical HPV prevalence is high in transplanted women. In comparison the overall anal hrHPV detection rate is even higher, suggesting that regular anal screening should be discussed in immunocompromised transplant recipients.